A meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure

American Journal of Cardiovascular Drugs

Volumn 5, Issue 2, 2005, Pages 131-140

  Baguet, Jean Philippe ^a   Robitail, Stephane ^b   Boyer, Laurent ^b   Debensason, David ^b   Auquier, Pascal ^b,c  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; IRBESARTAN; LERCANIDIPINE; LOSARTAN; RAMIPRIL; SPIRONOLACTONE; VALSARTAN;

ARTICLE; BLOOD PRESSURE REGULATION; CALCULATION; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; FOLLOW UP; FRANCE; HUMAN; HYPERTENSION; META ANALYSIS; METHODOLOGY; MONOTHERAPY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS; DIURETICS; FRANCE; HUMANS; HYPERTENSION; INDAPAMIDE; MEDICAL RECORDS; MIDDLE AGED; TREATMENT OUTCOME;

EID: 14944342227     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200505020-00007     Document Type: Article

References (93)

1. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289: 2363-9
2. Girerd X, Mourad JJ, Vaisse B. Estimation of the number of patients treated for hypertension, diabetes or hyperlipidemia in France: FLAHS study 2002 [in French]. Arch Mal Coeur Vaiss 2003; 96: 750-3
3. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003 Jun; 21 (6): 1011-53
4. Waeber B. Stratégies de traitement dans l'hypertension artérielle essentielle. Rev Prat 1999; 49: 520-5
5. Gifford Jr RW, Borazanian RA. Traditional first-line therapy: overview of medical benefits and side effects. Hypertension 1989; 13: 1119-24
6. Collins R, Peto R, McMahon S, et al. Blood pressure, stroke and coronary heart disease: part 2. Short term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-38
7. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-72
8. Douglas JG, Bakris GL, Epstein M, et al. Management of high blood pressure in African Americans: consensus statement of the hypertension in African Americans working group of the International Society on Hypertension in Blacks. Arch Intern Med 2003; 163: 2525-41
9. Cucherat M. Méta-analyse des essais thérapeutiques. Paris: Masson, 1997
10. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12
11. Conlin PR, Spence JD, Williams B, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000; 13: 418-26
12. Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press 1998; 7: 53-9
13. Reif M, White WB, Fagan TC, et al. Effects of candesartan cilexetil inpatients with systemic hypertension: Candesartan Cilexetil Study investigators. Am J Cardiol 1998; 82: 961-5
14. Manolis AJ, Grossman E, Jelakovic B, et al. Effects of losartan and candesartan monotherapy and losartan/HCTZ combination therapy in patients with mild to moderate hypertension: losartan trial investigators. Clin Ther 2000; 22: 1186-203
15. McInnes GT, O'Kane KP, Jonker J, et al. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population. J Hum Hypertens 1997; 11: S75-80
16. Zuschke CA, Keys I, Munger MA, et al. Candesartan cilexetil: comparison of once-daily versus twice-daily administration for systemic hypertension: Candesartan Cilexetil Study investigators. Clin Ther 1999; 21: 464-74
17. Kassler-Taub K, Littlejohn T, Elliott W, et al. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension: Irbesartan/Losartan Study investigators. Am J Hypertens 1998; 11: 445-53
18. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001; 3: 283-91, 318
19. Coca A, Calvo C, Garcia-Puig J, et al. A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL study (Monitorizacion Ambulatoria Presion Arterial APROVEL). Clin Ther 2002; 24: 126-38
20. Chiou KR, Chen CH, Ding PY, et al. Randomized, double-blind comparison of irbesartan and enalapril for treatment of mild to moderate hypertension. Zhonghua Yi Xue Za Zhi (Taipei) 2000; 63: 368-76
21. Stumpe KO, Haworth D, Hoglund C, et al. Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension. Blood Press 1998; 7: 31-7
22. Von zur Muhler B, Kahan T, Hagg A, et al. Treatment with irbesartan or atenolol improves endothelial function in essential hypertension. J Hypertens 2001; 19: 1813-8
23. Kurland L, Melhus H, Karlsson J, et al. Aldosterone synthase (CYP11B2)-344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. Am J Hypertens 2002; 15: 389-93
24. Oparil S, Barr E, Elkins M, et al. Efficacy, tolerability, and effects on quality of life of losartan, alone or with HCTZ, versus amlodipine, alone or with HCTZ, in patients with essential hypertension. Clin Ther 1996; 18: 608-25
25. Lacourciere Y, Poirier L, Lefebvre J, et al. Antihypertensive effects of amlodipine and HCTZ in elderly patients with ambulatory hypertension. Am J Hypertens 1995; 8: 1154-9
26. Chan JC, Critchley JA, Tomlinson B, et al. Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus. Am J Nephrol 1997; 17: 72-80
27. Sakata K, Yoshida H, Obayashi K, et al. Effects of losartan and its combination with quinapril on the cardiac sympathetic nervous system and neurohormonal status in essential hypertension. J Hypertens 2002; 20: 103-10
28. Chanudet X, De Champvallins M. Antihypertensive efficacy and tolerability of low-dose perindopril/indapamide combination compared with losartan in the treatment of essential hypertension. Int J Clin Pract 2001; 55: 233-9
29. Samra SS, Dongre N, Ballary C, et al. Comparison of the efficacy, safety and tolerability of telmisartan with losartan in Indian patients with mild to moderate hypertension: a pilot study. J Indian Med Assoc 2003; 101: 327-8
30. Conlin PR, Elkins M, Liss C, et al. A study of losartan, alone or with HCTZ vs nifedipine GITS in elderly patients with diastolic hypertension. J Hum Hypertens 1998; 12: 693-9
31. Chan P, Tomlinson B, Huang TY, et al. Double-blind comparison of losartan, lisinopril, and metolazone in elderly hypertensive patients with previous angiotensin-converting enzyme inhibitor-induced cough. J Clin Pharmacol 1997; 37: 253-7
32. Nielsen S, Dollerup J, Nielsen B, et al. Losartan reduces albuminuria in patients with essential hypertension: an enalapril controlled 3 months study. Nephrol Dial Transplant 1997; 12: 19-23
33. Oparil S, Guthrie R, Lewin AJ, et al. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan: Irbesartan/Losartan Study investigators. Clin Ther 1998; 20: 398-409
34. Hung MJ, Lin FC, Cherng WJ, et al. Comparison of antihypertensive efficacy and tolerability of losartan and extended-release felodipine in patients with mild to moderate hypertension. J Formos Med Assoc 1999; 98: 403-9
35. Chung O, Hinder M, Sharma AM, et al. Comparison of the efficacy and safety of losartan (50-100 mg) with the T-type calcium channel blocker mibefradil (50-100 mg) in mild to moderate hypertension. Fundam Clin Pharmacol 2000; 14: 31-41
36. Roca-Cusachs A, Oigman W, Lepe L, et al. A randomized, double-blind comparison of the antihypertensive efficacy and safety of once-daily losartan compared to twice-daily captopril in mild to moderate essential hypertension. Acta Cardiol 1997; 52: 495-506
37. Dahlof B, Keller SE, Makris L, et al. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens 1995; 8: 578-83
38. Dahlof B, Lindholm LH, Carney S, et al. Main results of the losartan versus amlodipine (LOA) study on drug tolerability and psychological general well-being: LOA Study Group. J Hypertens 1997; 15: 1327-35
39. Vidt DG, White WB, Ridley E, et al. A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM study II. J Hum Hypertens 2001; 15: 475-80
40. Bakris G, Gradman A, Reif M, et al. Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. J Clin Hypertens (Greenwich) 2001; 3: 16-21
41. Lacourciere Y, Belanger A, Godin C, et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int 2000; 58: 762-9
42. White WB, Sica DA, Calhoun D, et al. Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising. Am Heart J 2002; 144: 657-65
43. Li Y, Liu G, Jiang B, et al. A comparison of initial treatment with losartan/HCTZ versus losartan monotherapy in chinese patients with mild to moderate essential hypertension. Int J Clin Pract 2003; 57: 673-7
44. Rajzer M, Klocek M, Kawecka-Jaszcz K. Effect of amlodipine, quinapril, and losartan on pulse wave velocity and plasma collagen markers in patients with mild-to-moderate arterial hypertension. Am J Hypertens 2003; 16: 439-44
45. Hegner G, Faust G, Freytag F, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to HCTZ. Eur J Clin Pharmacol 1997; 52: 173-7
46. Fogari R, Preti P, Derosa G, et al. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Eur J Clin Pharmacol 2002; 58: 177-80
47. Corea L, Cardoni O, Fogari R, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther 1996; 60: 341-6
48. Holwerda NJ, Fogari R, Angeli P, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens 1996; 14: 1147-51
49. Neutel J, Weber M, Pool J, et al. Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours. Clin Ther 1997; 19: 447-58
50. Pesant Y, Marc-Aurele J, Bielmann P, et al. Metabolic and antihypertensive effects of nebivolol and atenolol in normometabolic patients with mild-to-moderate hypertension. Am J Ther 1999; 6: 137-47
51. Cleophas TJ, van der Mey N, van der Meulen J, et al. Quality of life before and during antihypertensive treatment: a comparative study of celiprolol and atenolol. Am J Ther 1997; 4: 117-22
52. Os I, Hotnes T, Dollerup J, et al. Comparison of the combination of enalapril and a very low dose of HCTZ with atenolol in patients with mild-to-moderate hypertension: Scandinavian Study Group. Am J Hypertens 1997; 10: 899-904
53. Campelo M, Polonia J, Serrao P, et al. Evaluation of the sympathetic nervous system using heart rate variability and plasma hormones in hypertensive patients treated with cilazapril and atenolol. Cardiology 1996; 87: 402-8
54. Annentano RL, Graf S, Ramirez AJ, et al. Mechanical vs intrinsic components in the improvement of brachial arterial compliance: comparison of the effects of atenolol versus ramipril in hypertensive patients. Medicina (B Aires) 2001; 61: 535-40
55. Webb DJ, Hutcheson MJ, Robertson MP, et al. A comparison of atenolol and long-acting trimazosin in mild to moderate essential hypertension. Scott Med J 1985; 30: 106-10
56. Beevers DG, Blackwood RA, Garnham S, et al. Comparison of lisinopril versus atenolol for mild to moderate essential hypertension. Am J Cardiol 1991; 67: 59-62
57. Dallocchio M, Gosse P, Fillastre JP, et al. Rilmenidine, a new antihypertensive agent in the first line treatment of essential arterial hypertension: multicenter double-blind study versus atenolol [in French]. Presse Med 1991; 20: 1265-71
58. Rorive G, Creytens G, Ruhwiedel M, et al. Comparative study of the efficacy and tolerance of perindopril, a new converting enzyme inhibitor and of atenolol, a beta blocker [in French]. Rev Med Liege 1990; 45: 62-8
59. Baez MA, Garg DC, Jallad NS, et al. Antihypertensive effect of doxazosin in hypertensive patients: comparison with atenolol. Br J Clin Pharmacol 1986; 21: 63S-7S
60. Lijnen P, Fagard R, Staessen J, et al. Short-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension. J Cardiovasc Pharmacol 1988; 12: 461-6
61. Hakamaki T, Lehtonen A. Metabolic effects of spirapril and atenolol: results from a randomized, long-term study. Int J Clin Pharmacol Ther 1997; 35: 227-30
62. Elijovich F, Laffer CL, Schiffrin EL. The effects of atenolol and zofenopril on plasma atrial natriuretic peptide are due to their interactions with target organ damage of essential hypertensive patients. J Hum Hypertens 1997; 11: 313-9
63. Frei M, Kuster L, Gardosch von Krosigk PP, et al. Moxonidine and HCTZ in combination: a synergistic antihypertensive effect. J Cardiovasc Pharmacol 1994; 24: S25-8
64. Emeriau JP, Knauf H, Pujadas JO, et al. A comparison of indapamide SR 1.5mg with both amlodipine 5mg and HCTZ 25mg in elderly hypertensive patients: a randomized double-blind controlled study. J Hypertens 2001; 19: 343-50
65. Lacourciere Y. A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension. Clin Ther 2000; 22: 1213-24
66. Dey HM, Soufer R, Hoffer P, et al. Comparison of nifedipine GITS and HCTZ in the management of elderly patients with stage I-III diastolic hypertension. Am J Hypertens 1996; 9: 598-606
67. Reisin E, Weir MR, Falkner B, et al. Lisinopril versus HCTZ in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) study group. Hypertension 1997; 30: 140-5
68. Fariello R, Dal Palu C, Pessina A, et al. Antihypertensive efficacy of urapidil versus HCTZ alone in patients with mild to moderate essential hypertension and of their combination in nonresponders to monotherapy. Drugs 1990; 40: 60-2
69. Kuo SW, Pei-Dee , Hung YJ, et al. Effect of indapamide SR in the treatment of hypertensive patients with type 2 diabetes. Am J Hypertens 2003; 16: 623-8
70. Guez D, Mallion JM, Degaute JP, et al. Treatment of hypertension with indapamide 1.5mg sustained-release form: synthesis of results. Arch Mal Coeur Vaiss 1996; 89: 17-25
71. Martina B, Weinbacher M, Drewe J, et al. Effects of losartan titrated to losartan/HCTZ and amlodipine on blood pressure and peripheral capillary microcirculation in patients with mild-to-moderate hypertension. J Hum Hypertens 1998; 12: 473-8
72. Zidek W, Spiecker C, Knaup G, et al. Comparison of the efficacy and safety of nifedipine coat-core versus amlodipine in the treatment of patients with mild-to-moderate essential hypertension: Hypertension Study Group. Clin Ther 1995; 17: 686-700
73. Zanchetti A, Omboni S, La Commare P, et al. Efficacy, tolerability, and impact on quality of life of long-term treatment with manidipine or amlodipine in patients with essential hypertension. J Cardiovasc Pharmacol 2001; 38: 642-50
74. Delles C, Klingbeil AU, Schneider MP, et al. Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension. Am J Hypertens 2003; 16: 1030-5
75. Fernandez-Andrade C, Russo D, Iversen B, et al. Comparison of losartan and amlodipine in renally impaired hypertensive patients. Kidney Int Suppl 1998; 68: S120-4
76. Phillips RA, Kloner RA, Grimm RH, et al. The effects of amlodipine compared to losartan in patients with mild to moderately severe hypertension. J Clin Hypertens (Greenwich) 2003; 5: 17-23
77. Kloner RA, Weinberger M, Pool JL, et al. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension: comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) study investigators. Am J Cardiol 2001; 87: 727-31
78. Grimm Jr RH, Black H, Rowen R, et al. Amlodipine versus chlorthalidone versus placebo in the treatment of stage I isolated systolic hypertension. Am J Hypertens 2002; 15: 31-6
79. Zannad F, Bernaud CM, Fay R. Double-blind, randomized, multicentre comparison of the effects of amlodipine and perindopril on 24h therapeutic coverage and beyond in patients with mild to moderate hypertension: General Physicians Investigators' Group. J Hypertens 1999; 17: 137-46
80. Palatini P, Malacco E, Di SS, et al. Trough : peak ratio and smoothness index in the evaluation of 24-h blood pressure control in hypertension: a comparative study between valsartan/HCTZ combination and amlodipine. Eur J Clin Pharmacol 2002; 57: 765-70
81. Pandita-Gunawardena ND, Clarke SE. Amlodipine lowers blood pressure without affecting cerebral blood flow as measured by single photon emission computed tomography in elderly hypertensive subjects. Age Ageing 1999; 28: 451-7
82. Romito R, Pansini MI, Perticone F, et al. Comparative effect of lercanidipine, felodipine, and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercanidipine in Adults (LEAD) Study. J Clin Hypertens (Greenwich) 2003; 5: 249-53
83. Martina B, Lorz W, Frach B, et al. The effects of mibefradil and enalapril on 24-hour blood pressure control and left ventricular mass in patients with mild to moderate hypertension: double-blind, randomized trial. J Cardiovasc Pharmacol 1999; 33: 647-51
84. Service des Recommandations et Références Professionnelles, Service d'Evaluation Economique. Prise en charge des patients adultes atteints d'Hypertension Artérielle Essentielle: recommandations cliniques et données économiques. Anaes Avril 2000
85. Gueyffier F, Boutitie F, Haugh M, et al. INDANA: a meta-analysis on individual patient data in hypertension. Protocol and preliminary results. Thérapie 1995; 50: 353-62
86. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research group. Arch Intern Med 1992; 152: 56-64
87. Himmelmann A, Hedner T, Hansson L, et al. Isolated systolic hypertension: an important cardiovascular risk factor. Blood Pressure 1998; 7: 197-207
88. Mancia G, Bombelli M, Lanzarotti A, et al. Systolic vs diastolic blood pressure control in the hypertensive patients of the PAMELA population. Arch Int Med 2002; 162: 582-6
89. London GM. Efficacy of indapamide 1.5mg, sustained release, in the lowering of systolic blood pressure. J Hum Hypertens 2004 Dec; 18 Suppl. 2: S9-14
90. Pahor M, Applegate WB, Williamson JD. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 2000; 356: 1949-54
91. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 9395: 1527-35
92. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363 (9426): 2022-31
93. Psaty BM, Lumley T, Furberg CD, et al. Heath outcomes associated with various antihypertensive therapies used as first-line agents: a network analysis. JAMA 2003; 289: 2534-44